CombinatoRx and privately held Neuromed Pharmaceuticals announced yesterday that they have closed their $28.8 million all-stock merger.
CombinatoRx issued approximately 14.9 million new shares to Neuromed stockholders and placed another 67.8 million new shares in escrow.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?